Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term acalabrutinib + venetoclax in newly diagnosed CLL patients at high infection risk who do not yet meet IWCLL criteria
2019-000270-29Phase 2Active
- Sponsor
- Rigshospitalet
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Short-term acalabrutinib + venetoclax with Observation (2 arms). Primary endpoint: Grade ≥3 infection-free survival. Started Jul 2019; status: active.
02
Drugs
acalabrutinibvenetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2019-000270-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000270-29.